Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

Returns vs FD rates

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Sanofi Casts Doubt on Market for Covid Shots Post-Pandemic

Completion of the transaction is subject to certain conditions and is expected to close within the next 3 months.

Sanofi India updates on divestment of Soframycin and Sofradex biz; Stock sheds near 2%

Will also acquire other legacy associated brands such as Sofradex (antibacterial cream), Sofracort (eye and ear drops), Soframycin-Tulle (cream) for India and Sri Lanka markets

Encube to buy anti-microbial brand Soframycin from Sanofi for Rs 125 cr

The transaction is expected to close within the next 3 months

Encube Ethicals to acquire Soframycin for India and Sri Lanka markets from Sanofi

Encube Ethicals has agreed to buy popular topical anti-microbial brand Soframycin and other brands from French drugmaker Sanofi for India and Sri Lanka markets for Rs 125 crore.

Encube Ethicals to buy Soframycin for Rs 125 crore for India & SL markets

Sanofi India rose 1.08% to Rs 8264.70 after the company announced divestment of Soframycin and Sofradex businesses.

Sanofi India gains on selling Soframycin, Sofradex biz

Sanofi India that upon completion of the transaction, the acquirer Encube Ethicals would be handed over rights to sell and distribute Soframycin and Sofradex in India and Sri Lanka.

Sanofi India To Divest Soframycin, Sofradex Brands For Rs 125 Crore

Sanofi picks Bank of America, BNP Paribas and JPMorgan to lead the IPO of its business manufacturing drug ingredients.

Sanofi Is Said to Select Banks for $1.2 Billion Ingredients IPO

Sanofi India Standalone September 2021 Net Sales At Rs 754.50 Crore, Up 9.89% Y-o-Y

Sanofi India rose 1.08% to Rs 8,179 after the company’s standalone net profit surged 298.64% to Rs 529.80 crore on a 9.88% rise in revenue from operations to Rs 754.50 crore in Q3 September 2021 over Q3 September 2020.

Sanofi India gains after Q3 September PAT grows 4-fold to Rs 530 cr

Radhika Shah will also be the Compliance Officer with effect from November 01, 2021 in place of Vaibhav Karandikar.

Sanofi India appoints Radhika Shah as Company Secretary and KMP; Stock climbs over 2%

Sanofi India Limited is engaged in the manufacture and sale of pharmaceutical products.

Sanofi India Ltd

Sanofi India Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Sanofi Casts Doubt on Market for Covid Shots Post-Pandemic

Sanofi India updates on divestment of Soframycin and Sofradex biz; Stock sheds near 2%

Encube to buy anti-microbial brand Soframycin from Sanofi for Rs 125 cr

Encube Ethicals to acquire Soframycin for India and Sri Lanka markets from Sanofi

Encube Ethicals to buy Soframycin for Rs 125 crore for India & SL markets

Sanofi India gains on selling Soframycin, Sofradex biz

Sanofi India To Divest Soframycin, Sofradex Brands For Rs 125 Crore

Sanofi Is Said to Select Banks for $1.2 Billion Ingredients IPO

Sanofi India Standalone September 2021 Net Sales At Rs 754.50 Crore, Up 9.89% Y-o-Y

Sanofi India gains after Q3 September PAT grows 4-fold to Rs 530 cr

Sanofi India Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Sanofi Casts Doubt on Market for Covid Shots Post-Pandemic

Sanofi India updates on divestment of Soframycin and Sofradex biz; Stock sheds near 2%

Encube to buy anti-microbial brand Soframycin from Sanofi for Rs 125 cr

Encube Ethicals to acquire Soframycin for India and Sri Lanka markets from Sanofi

Encube Ethicals to buy Soframycin for Rs 125 crore for India & SL markets

Sanofi India gains on selling Soframycin, Sofradex biz

Sanofi India To Divest Soframycin, Sofradex Brands For Rs 125 Crore

Sanofi Is Said to Select Banks for $1.2 Billion Ingredients IPO

Sanofi India Standalone September 2021 Net Sales At Rs 754.50 Crore, Up 9.89% Y-o-Y

Sanofi India gains after Q3 September PAT grows 4-fold to Rs 530 cr

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock